New drink promises faster muscle recovery for young athletes
NCT ID NCT07586839
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a drink containing caprylic acid and omega-3 fatty acids can help muscles recover strength after a tough workout. Twenty-eight healthy young men will take the supplement for seven days and do a muscle-damaging exercise. Researchers will measure muscle strength and fatigue before and up to 72 hours after exercise to see if the drink speeds up recovery compared to a control drink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a drink containing caprylic acid and omega-3 fatty acids
- What this could lead to
- If it works, this could point toward a simple nutritional supplement to speed up muscle recovery after intense exercise.
- What could go wrong
- This is a small, early-stage study in healthy young men only, so results may not apply to others. The effect may be small or no better than a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wageningen University and Research
RECRUITINGWageningen, Gelderland, 6708WD, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test